title: Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified?
authors.forename: A
authors.initials: A
authors.lastname: Tefferi
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D001157:Arterial Occlusive Diseases / Q000150:complications*; D001549:Benzamides / Q000009:adverse effects*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D058729:Peripheral Arterial Disease / Q000150:complications*; D010879:Piperazines / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines